The latest one-year and two-year results from ongoing multi-centre trials of ZEISS MyoCare lenses consistently demonstrate the slowing of progressive myopia in both Asian and Caucasian children, ZEISS has announced.
The data also confirms rapid adaptation to the lenses, which became available to Australian and New Zealand optometrist in July 2023.
The company has developed ZEISS MyoCare with a 7 mm diameter clear zone and ZEISS MyoCare S with a 9 mm diameter clear zone.
In two ongoing multi-centre clinical trials across China and Europe, ZEISS MyoCare lenses are being assessed to ensure a comprehensive and robust evaluation of their effectiveness in slowing myopia.
ZEISS Vision Care revealed the latest findings at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) held at Salt Lake City, US.
In Asian children, after two years of wear as compared to single vision lenses, the company reported that ZEISS MyoCare was shown to have slowed myopia progression on average by 0.44 D and 0.20 mm and ZEISS MyoCare S by 0.41 D and 0.17 mm.1
In Caucasian children, after 12 months, ZEISS MyoCare slowed myopia progression on average by 0.21 D and 0.14 mm and significantly reduced the risk of fast progression.2,3 Additionally, ZEISS MyoCare lenses were seen to significantly slow myopia irrespective of past progression.4
Although progression of myopia was higher in Asian eyes as compared to European eyes, ZEISS MyoCare lenses were effective in slowing myopia equally across both races.5
The company also reported children who adapt quickly to new lenses are more likely to wear them consistently, and good compliance has been determined to be a key factor for slowing myopia.
“Results indicated that 84% of ZEISS MyoCare lens wearers adapted to the lenses in less than three days. Additionally, when queried on subjective impressions, a full 95%, 93% and 96% reported either ‘good or very good’ distance vision, near vision, and vision when playing sports or with other daily activities, respectively,”6 ZEISS stated.
The posters presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) can be found here.
References
1. Chen X, et al. (2025, May 4-8). Slowing myopia progression with cylindrical annular refractive elements (CARE)- results from a 2-year prospective multi-central trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
2. Alvarez-Peregrina, C., et al. (2025, May 4-8). Analysis of fast myopia progression and eye growth reversal in the Clinical Evaluation of MyoCare in Europe (CEME) study after 12 months wearing CARE lenses. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
3. Alvarez-Peregrina, C., et al. Clinical Evaluation of MyoCare in Europe – the CEME Study Group. Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results. Ophthalmic Physiol Opt. 2025 Apr 29. doi: 10.1111/opo.13517. Epub ahead of print. PMID: 40296784.
4. Ohlendorf, A., et al. (2025, May 4-8). Myopia progression in children: Comparison of progression one year before and during participation in a randomized controlled clinical trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
5. Sankaridurg, P., et al. (2025, May 4-8). Myopia control efficacy in Asian versus European eyes with spectacle lenses incorporating cylindrical annular refractive elements (CARE). [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
6. Sanchez-Tena, M.A., et al. (2025, May 4-8). Adaptation and Visual Performance of CARE Spectacle Lenses: Findings from the Clinical Evaluation of MyoCare in Europe (CEME) Study. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
